AnGes, Inc. (AJW.F)

0.2380 +0.0020 (+0.85%) At close: 09:49PM CEST

AnGes, Inc.

Saito Bio-Incubator
1st Floor 7-7-15, Saito-asagi
Ibaraki 567-0085
Japan

https://www.anges.co.jp

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 145

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Ei Yamada M.D., Ph.D.	CEO, President & Representative Director	N/A	N/A	1950
Mr. Naoya Sato	Director of Corporate Development & Director	N/A	N/A	1960

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of ischemic diseases. The company is also developing NF-kB Decoy Oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases, including low back pain; drugs for treating atopic dermatitis and asthma; medical devices for the prevention of vascular medicine; cervical intraepithelial neoplasia therapeutic vaccines for cervical cancer; and DNA vaccines for high blood pressure through collaborative research agreement with Osaka University. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was incorporated in 1999 and is headquartered in Ibaraki, Japan.

Corporate governance

AnGes, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.